Novkovic S, Selemetjev S, Miljus J, Zivaljevic V, Dunderovic D, Milinkovic M
Int J Mol Sci. 2025; 26(3).
PMID: 39941022
PMC: 11818258.
DOI: 10.3390/ijms26031253.
Cendra A, Pekarek L, Pedrejon B, Bernier L, Cervantes E, Cendra C
J Cancer. 2025; 16(1):241-264.
PMID: 39744583
PMC: 11660124.
DOI: 10.7150/jca.101395.
Sabi E
Front Oncol. 2024; 14:1474267.
PMID: 39558949
PMC: 11570407.
DOI: 10.3389/fonc.2024.1474267.
Zhang T, Yuan B, Yu S
Int J Gen Med. 2024; 17:4681-4699.
PMID: 39429957
PMC: 11490214.
DOI: 10.2147/IJGM.S487239.
Armos R, Bojtor B, Papp M, Illyes I, Lengyel B, Szili B
Int J Mol Sci. 2024; 25(17).
PMID: 39273308
PMC: 11395536.
DOI: 10.3390/ijms25179362.
Role of circRNAs in regulating cell death in cancer: a comprehensive review.
Saadh M, Ehymayed H, Alazzawi T, Fahdil A, Athab Z, Yarmukhamedov B
Cell Biochem Biophys. 2024; 83(1):109-133.
PMID: 39243349
DOI: 10.1007/s12013-024-01492-6.
Plasma miRNA-146b-3p, -222-3p, -221-5p, -21a-3p Expression Levels and Methylation: Diagnostic Potential and Association with Clinical and Pathological Features in Papillary Thyroid Cancer.
Kazlauskiene M, Klimaite R, Kondrotiene A, Dauksa A, Dauksiene D, Verkauskiene R
Int J Mol Sci. 2024; 25(15).
PMID: 39125979
PMC: 11313006.
DOI: 10.3390/ijms25158412.
Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing.
Lukyanov S, Titov S, Kozorezova E, Demenkov P, Veryaskina Y, Korotovskii D
Int J Mol Sci. 2024; 25(13).
PMID: 39000197
PMC: 11241318.
DOI: 10.3390/ijms25137090.
Exosomal noncoding RNAs: decoding their role in thyroid cancer progression.
Sun W, Jiang C, Liu Q, Wang N, Huang R, Jiang G
Front Endocrinol (Lausanne). 2024; 15:1337226.
PMID: 38933820
PMC: 11199389.
DOI: 10.3389/fendo.2024.1337226.
Unraveling the Significance of DGCR8 and miRNAs in Thyroid Carcinoma.
Rodrigues L, Da Cruz Paula A, Soares P, Vinagre J
Cells. 2024; 13(7.
PMID: 38607000
PMC: 11011343.
DOI: 10.3390/cells13070561.
miRNA-221 and miRNA-483-3p Dysregulation in Esophageal Adenocarcinoma.
Bozzarelli I, Orsini A, Isidori F, Mastracci L, Malvi D, Lugaresi M
Cancers (Basel). 2024; 16(3).
PMID: 38339342
PMC: 10854562.
DOI: 10.3390/cancers16030591.
MicroRNA Expression Profiling-Potential Molecular Discrimination of Papillary Thyroid Carcinoma Subtypes.
Silaghi H, Pop L, Georgescu C, Muntean D, Crisan D, Silaghi P
Biomedicines. 2024; 12(1).
PMID: 38255241
PMC: 10813560.
DOI: 10.3390/biomedicines12010136.
Effective Use of microRNA, BRAF and Sonographic Risk Assessment in Bethesda III Thyroid Nodules Requires a Different Approach to Nodules with Features of Nuclear Atypia and Other Types of Atypia.
Slowinska-Klencka D, Popowicz B, Kulczycka-Wojdala D, Szymanska B, Duda-Szymanska J, Wojtaszek-Nowicka M
Cancers (Basel). 2023; 15(17).
PMID: 37686562
PMC: 10486535.
DOI: 10.3390/cancers15174287.
Upregulation and the clinical significance of KCNQ1OT1 and HAGLROS lncRNAs in papillary thyroid cancer: An observational study.
Mutlu Icduygu F, Akgun E, Ozgoz A, Hekimler Ozturk K, Sengul D, Alp E
Medicine (Baltimore). 2023; 102(29):e34379.
PMID: 37478216
PMC: 10662889.
DOI: 10.1097/MD.0000000000034379.
Novel Susceptibility Genes Drive Familial Non-Medullary Thyroid Cancer in a Large Consanguineous Kindred.
Majdalani P, Yoel U, Nasasra T, Fraenkel M, Haim A, Loewenthal N
Int J Mol Sci. 2023; 24(9).
PMID: 37175943
PMC: 10179265.
DOI: 10.3390/ijms24098233.
Emerging role of ferroptosis-related circular RNA in tumor metastasis.
Meng Y, Cao J, Li Y, Duan S, Zhou Z, Li J
Front Pharmacol. 2023; 14:1168458.
PMID: 37168995
PMC: 10164976.
DOI: 10.3389/fphar.2023.1168458.
Differential microRNA expression for diagnosis and prognosis of papillary thyroid cancer.
Ruiz-Pozo V, Cadena-Ullauri S, Guevara-Ramirez P, Paz-Cruz E, Tamayo-Trujillo R, Zambrano A
Front Med (Lausanne). 2023; 10:1139362.
PMID: 37089590
PMC: 10113479.
DOI: 10.3389/fmed.2023.1139362.
Identification of m6A-related lncRNAs for thyroid cancer recurrence.
Wang X, Su D, Wei Y, Liu S, Gao S, Tian H
Gland Surg. 2023; 12(1):39-53.
PMID: 36761480
PMC: 9906100.
DOI: 10.21037/gs-22-678.
MicroRNA expression profiling of RAS-mutant thyroid tumors with follicular architecture: microRNA signatures to discriminate benign from malignant lesions.
Macerola E, Poma A, Vignali P, Proietti A, Torregrossa L, Ugolini C
J Endocrinol Invest. 2023; 46(8):1651-1662.
PMID: 36749451
PMC: 10349002.
DOI: 10.1007/s40618-023-02023-5.
Modulatory role of miRNAs in thyroid and breast cancer progression and insights into their therapeutic manipulation.
Ahmed R, Samanta S, Banerjee J, Kar S, Dash S
Curr Res Pharmacol Drug Discov. 2022; 3:100131.
PMID: 36568259
PMC: 9780070.
DOI: 10.1016/j.crphar.2022.100131.